Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NRXP
NRXP | US
1.73
USD0.03
1.76%
NRXP | US
Loading StockChartView...
About NRXP
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
1.73
Open
1.64
High
1.75
Low
1.62
NRX Pharmaceuticals Inc. a clinical-stage pharmaceutical company develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington Delaware.
View LessNRXP | US
Risk
59.6
Sharpe
-0.33
Luna's Score
45/100
Recommendation
Sell
Luna says (NRXP | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
62.3%1 month
59.6%3 months
75.2%6 months
76.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.90
Debt to equity
-0.47
Debt to assets
1.63
Ent. to EBITDA
-0.15
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-23.26M
MarketCap
18.60M
MarketCap(USD)
18.60M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-682.61
Short ratio
5.82
Short perc.
5.99
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.37
Range1M
0.38
Range3M
1.15
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.37
Price X volume
1.29M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.15 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.90 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 75.24 | 72.80 | Par |
| Debt to Equity | -0.47 | -1.23 | Expensive |
| Debt to Assets | 1.63 | 0.25 | Expensive |
| Market Cap | 18.60M | 3.66B | Emerging |
